Form 4: Akebia Therapeutics Director LeAnne M. Zumwalt Receives Significant Equity Grants

Akebia Therapeutics, Inc. director LeAnne M. Zumwalt was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of her compensation.

Summary

• LeAnne M. Zumwalt, a Director of Akebia Therapeutics, Inc. (AKBA), was granted equity awards on June 10, 2025.
• She received 35,700 Restricted Stock Units (RSUs) at a price of $0.00. These RSUs will vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date, contingent on her continued service.
• Additionally, she was granted options to purchase 53,600 shares of common stock with an exercise price of $3.92 per share. These stock options also vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date, subject to her continued service.
• The stock options become exercisable on June 10, 2026, and expire on June 10, 2035.
• These grants were made pursuant to the Issuer's 2023 Stock Incentive Plan and the Fourth Amended and Restated Non-Employee Director Compensation Program.
• Following these transactions, Ms. Zumwalt beneficially owns 109,400 shares of common stock directly and 53,600 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document reports a standard equity compensation grant to a director, which is a neutral to slightly positive event as it aligns interests, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The equity grants align the director's interests with those of shareholders, as the value of the awards is tied to the company's stock performance.
• The grants serve as a form of compensation and retention for a key member of the company's board of directors.

Negatives

• The issuance of new equity (upon RSU vesting and option exercise) could lead to minor dilution for existing shareholders, although the amounts are typically small for individual director grants.

Future Outlook

The vesting schedule for the RSUs and stock options indicates a future commitment from the director to continued service, aligning with the company's long-term plans for its board.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries for compensating non-employee directors, aligning their incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a common practice across publicly traded companies, particularly in the biotech sector. The specific amounts granted would need to be compared against peer companies of similar market capitalization and stage of development to assess if they are within industry norms. Without specific peer data, a detailed comparison is not possible from this document alone.

Corporate Governance

Related Party Transactions

• The grant of equity awards to a director (LeAnne M. Zumwalt) constitutes a related party transaction, as directors are considered related parties to the company.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting/exercise of awards; improved alignment of director's interests with shareholder value.

Next Steps

• Continued service of LeAnne M. Zumwalt to Akebia Therapeutics, Inc.
• Vesting of 35,700 Restricted Stock Units on June 10, 2026, or earlier.
• Stock Options for 53,600 shares becoming exercisable on June 10, 2026, or earlier.

Key Dates

Keywords

Akebia Therapeutics, AKBA, SEC Form 4, insider transaction, beneficial ownership, restricted stock units, RSUs, stock options, equity compensation, director compensation, LeAnne M. Zumwalt, 2023 Stock Incentive Plan